For 2021, Texas Medicaid has designated pegfilgrastim-cbqv (Udenyca®, Coherus Biosciences) the preferred pegfilgrastim on the Preferred Drug List (PDL). Udenyca® coverage details are available here.
Please contact marketaccess@coherus.com for additional information.
Posted 3/15/2021
For 2021, Texas Medicaid has designated pegfilgrastim-cbqv (Udenyca®, Coherus Biosciences) the preferred pegfilgrastim on the Preferred Drug List (PDL). Udenyca® coverage details are available here.
Please contact marketaccess@coherus.com for additional information.
Posted 3/15/2021
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
